Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib Phase 2 in Moderate-to-Severe Atopic Dermatitis
NCT02576938Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Percentage of Participants With a 50% or Greater Reduction in the Eczema Area and Severity Index at 16 weeks. Started Feb 2016; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02576938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576938.